Clinical trial
Celecoxib and Erlotinib in Treating Patients With Liver Cancer
NCT00293436 · University of California, San Francisco, Other · Withdrawn
Key facts
| NCT number | NCT00293436 |
|---|---|
| Title | Celecoxib and Erlotinib in Treating Patients With Liver Cancer |
| Official title | A Phase I/II Study of Celecoxib and Erlotinib Hydrochloride as Adjuvant Therapy for High Risk Patients With a History of Hepatocellular Carcinoma |
| Lead sponsor | University of California, San Francisco, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Withdrawn |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Liver Cancer |
| Intervention type | Drug, Procedure |
| Interventions | celecoxib, erlotinib hydrochloride, adjuvant therapy |
| Enrollment | 0 |
| Start date | Jan 1, 2005 |
| First posted | Feb 17, 2006 |
| Last update posted | Sep 17, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: